Zucara Therapeutics Inc., of Vancouver, British Columbia, said it received a C$525,000 (US$391,866) investment from Canadian partners: Accel-Rx Health Sciences Accelerator, The Centre for Drug Research and Development and MaRS Innovation. Zucara is a preclinical-stage company working on a long-term approach to prevent hypoglycemia in patients with diabetes. The company said it plans to seek series A funding next year to take it through clinical studies, set to start in 2018.